Scandion Oncology obtains EU Funding for SCO-101 in drug resistant breast cancer patients
Scandion Oncology A/S (”Scandion” or ”the Company”) announces today that the Company has obtained a SME Instrument phase I grant from EU.The SME phase I grant amounts to DKK 350.000 and will be used for a comprehensive market analysis of SCO-101 in breast cancer therapy, a complete regulatory and clinical validation strategy and to finalize the design of a Phase II clinical trial aimed at positioning SCO-101 in the breast cancer population with the most relevant endpoints. The grant will also be used to further develop Scandion Oncology’s business development strategy. It also includes a